Literature DB >> 10629011

Macrolide resistance in group A streptococci.

D Savoia1, C Avanzini, K Bosio, G Volpe, D Carpi, G Dotti, M Zucca.   

Abstract

Two hundred and twenty one Streptococcus pyogenes isolates collected from throat swabs of untreated children with uncomplicated pharyngotonsillitis living in two centres situated in the north of Italy were tested to evaluate their macrolide resistance phenotype. Isolates were also typed for T protein and assayed for opacity factor (OF) and protease production. Resistance to macrolides was found to be similar in the two centres. Fifty-one point two per cent of Torino strains and 43.5% of Pinerolo strains were not inhibited by erythromycin. Resistant strains belonged to one of three phenotypes: CR, constitutive resistance (37.9 and 42.5% in Torino and Pinerolo, respectively); IR, inducible resistance (40.9 and 17. 5%); NR, new resistance phenotype (21.2 and 40%). All the resistant and some of the susceptible strains were analysed by pulsed-field gel electrophoresis and genomic patterns were defined on the basis of band size and number. Five DNA profiles were found among erythromycin-resistant strains: three patterns characterized the NR resistance phenotype and one each the IR and CR phenotypes. The distribution of resistant strains according to their genomic patterns appears to be related to the resistance phenotype and only in some cases to the T serotype of bacteria. We conclude that the S. pyogenes strains analysed are genetically heterogeneous and therefore the high rate of erythromycin resistance observed is not caused by the spread of a single clone nor is it related to a particular serotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10629011     DOI: 10.1093/jac/45.1.41

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  8 in total

1.  Susceptibility to telithromycin in 1,011 Streptococcus pyogenes isolates from 10 central and Eastern European countries.

Authors:  Kensuke Nagai; Peter C Appelbaum; Todd A Davies; Linda M Kelly; Dianne B Hoellman; Arjana Tambic Andrasevic; Liga Drukalska; Waleria Hryniewicz; Michael R Jacobs; Jana Kolman; Jolanta Miciuleviciene; Marina Pana; Lena Setchanova; Marianne Konkoly Thege; Helena Hupkova; Jan Trupl; Pavla Urbaskova
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

2.  Survey of phenotypic and genetic features of streptococcus pyogenes strains isolated in Northwest Italy.

Authors:  Simona Bianco; Tiziano Allice; Mario Zucca; Dianella Savoia
Journal:  Curr Microbiol       Date:  2005-12-26       Impact factor: 2.188

3.  Association between resistance to erythromycin and the presence of the fibronectin binding protein F1 gene, prtF1, in Streptococcus pyogenes isolates from German pediatric patients.

Authors:  Maria Haller; Kirsten Fluegge; Sandra Jasminder Arri; Brit Adams; Reinhard Berner
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

4.  Erythromycin-resistant pharyngeal isolates of Streptococcus pyogenes recovered in Italy.

Authors:  Giordano Dicuonzo; Ersilia Fiscarelli; Giovanni Gherardi; Giulia Lorino; Fabrizio Battistoni; Simona Landi; Marina De Cesaris; Tommasangelo Petitti; Bernard Beall
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

5.  Bacteriology and antibiotic sensitivity of tonsillar diseases in Chinese children.

Authors:  Qian Wang; Jingdong Du; Chen Jie; Hong Ouyang; Renzhong Luo; Wei Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-05-27       Impact factor: 2.503

6.  DNA methylase activity as a marker for the presence of a family of phage-like elements conferring efflux-mediated macrolide resistance in streptococci.

Authors:  T A Figueiredo; S I Aguiar; J Melo-Cristino; M Ramirez
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

7.  Activities of a new fluoroketolide, HMR 3787, and its (des)-fluor derivative RU 64399 compared to those of telithromycin, erythromycin A, azithromycin, clarithromycin, and clindamycin against macrolide-susceptible or -resistant Streptococcus pneumoniae and S. pyogenes.

Authors:  K Nagai; T A Davies; L M Ednie; A Bryskier; E Palavecino; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

8.  The Treatment of Severe Group A Streptococcal Infections.

Authors:  Anna Norrby-Teglund; S. Ragnar Norrby; Donald E. Low
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.